Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial.
Van Oirschot M, Bergman A, Verbakel WFAR, Ward L, Gagne I, Huang V, Chng N, Houston P, Symes K, Thomas CG, Basran P, Bowes D, Harrow S, Olson R, Senan S, Warner A, Palma DA, Gaede S.
Van Oirschot M, et al. Among authors: houston p.
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):1016-1021. doi: 10.1016/j.ijrobp.2022.01.002. Epub 2022 Jan 12.
Int J Radiat Oncol Biol Phys. 2022.
PMID: 35031340
Clinical Trial.